Glaucoma ; diagnosis ; therapy ; Humans ; Research

Glaucoma is a common blinding eye disease mainly characterized by optic nerve damage.Lowing intraocular pressure is still the main managing method of glaucoma up to now.However,although the intraocular pressure is reasonably controlled,optic nerve damage is difficult to recovery and sustainable development in some patients.Therefore,the pathogenesis and prevention and treatment of glaucoma have always been the hot spot of the research of glaucoma in recent years.Even though the big progresses have been made in the experimental research of optical nerve injury and repair,little good evidence has been seen in the clinical management of glaucoma neuroprotection.In recent years,genomics study,stem cells study,molecular biological study,electronic technology application in medical research,especially the rise of big data era laid a good basis for the neuroprotection of glaucoma.Ophthalmologists should focus on new insights into the potential and beyond impact factors in the precise individual therapy of glaucoma neuroprotection.

The following progresses have been recently made on glaucoma in Zhongshan Ophthalmic Center,covering clinical and basic researches on molecular genetics and epidemiology,stem eells,pathogenesis of calcium and adenosine,neuroprotection,etc. New insight has been shown into about 30 papers published in international peer-review(SCI)journals.

The paper briefly reports the preliminary research results,focusing on the pathogenesis,mechanisms and interference strategies of glaucoma and myopia.(1)The myocilin gene has been found a mutation in Pro370Leu in GZ.1 and PN.1 glaucoma pedigrees,and the theory of protein misfolding and mitochondria dysfunction in glaucoma was then firefly elucidated.We further explored the modulation of wound healing by siRNA,neuro-protection by targeting drugs with drug deliver system and stem cells/iPS in glaucoma therapy,which offer a revolutionary strategy for glaucoma:differential treatment for specific stages.(2)Natural myopia model was successfully established in rhesus monkeys and retinal mechanisms and central nervous system were both found to play an important role during myopia development,and a variety of new optical interventions were therefore employed on human beings by series of randomized,controlled,double-masked prospective clinical trials.All these preliminary results offer a new insight into the new model for the diagnosis and treatment of glaucoma and myopia.

Replacement therapy of stem cells transplantation represents a potential treatment for neural retinal diseases.Despite the encouraging results in laboratory,the clinical application of cells replacement therapy is still difficult because the limitation of seed cells,immunologic rejection,oncogenicity and ethical problems,etc.Recent breakthrough in somatic reprogramming provides a promising solution overcoming these obstacles.Further researches on virus-free reprogramming will make the clinical application of stem cell replacement therapy possible.

OBJECTIVE:To study the effects of grape seed proanthocyanidin(GSP)on the transmembrane transport of sodium glycocholate (GA) and sodium taurocholate (TA) in colon glandular cell Caco-2. METHODS:Caco-2 model was used,and RP-HPLC was conducted to determine the contents of GA and TA in cell culture medium. The test was divided into GSP group, GA group,TA group,GSP+GA group and GSP+TA group,the transport volumes of transporting GA and TA from Transwell apical (AP)side to basolateral(BL)side by Caco-2 cell at 0,2,4,8 h were detected,respectively. RESULTS:The linear ranges of GA and TA were 0.05-1.2 mmol/L(R2=0.9999). With the time passing,transport volumes of GA and TA in BL site in GA group and TA group were sharply increased;while the transport volumes were obviously decreased after adding GSP,with statistical signifi-cance(P<0.01). CONCLUSIONS:GSP has inhibitory effect on the transmembrane transport of GA and TA in Caco-2 cell.

strains that could produce raw starch-digesting glucoamylase were isolated from soil and mildewed rice.The highest raw starch-digesting glucoamylase activity strain named OR-1 was identified as Rhizopus.sp.The raw starch-digesting glucoamylase activity of the strain is 90U/mL.Through UV and NTG mutagenesis,the raw starch-digesting glucoamylase activity raised to 200U/mL and 325U/mL respectively.The RDA were 70% and 65% respectively.

Angiogenesis Inhibitors ; adverse effects ; therapeutic use ; Angiotensin-Converting Enzyme Inhibitors ; therapeutic use ; Antibodies, Monoclonal ; adverse effects ; therapeutic use ; Antibodies, Monoclonal, Humanized ; Aspirin ; administration & dosage ; therapeutic use ; Bevacizumab ; Hemorrhage ; chemically induced ; Humans ; Hypertension ; chemically induced ; drug therapy ; Intestinal Perforation ; chemically induced ; surgery ; Neoplasms ; drug therapy ; Proteinuria ; chemically induced ; Thromboembolism ; chemically induced ; drug therapy

Objective To investigate the toxicity and transfection efficiency of PEI-mediated plasmid DNA encoding myocilin (MYOC) gene transfected into trabecular meshwork.Design Experimental study.Participants SD rats.Methods PEI and plasmid encoding MYOC gene complex was prepared and 20?l PEI/DNA complex was directly injected into anterior chamber of SD rat by microinjection. The eyes were extracted at day 1,3,7,and 14 after injection for the structure analysis of trabecular meshwork by HE staining and transmission electron microscope.Expression of the transferred myocilin gene was monitored by fluorescence microscopy. Main Outcome Measures HE staining,immunohistochemistry and electron microscope.Results No significant toxicity or inflammation was detected under the HE staining and electron microscope.PEI/DNA complex were seen in cytoplasm of trabecular meshwork cells. The fluorescence intensity of myocilin expression in the trabecular meshwork cells was increasing with time and peaked on clays 3 and declined afterward.Conclusion Plasmid DNA mediated by PEI could be efficiently transfected into trabecular meshwork cells by directly injecting into anterior chamber without any toxicity.